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responders (p=0.03) and a higher rate of males (p=0.06) as well as pts with
previous myocardial infarction (p=0.06) in this group. There were no statisti-
cally significant differences in sex, BMI or diabetics.
Additional analysis of response versus weight showed an association with Pts
weighing less than 75kg who were more likely to be double responders
(p=0.02)
 Conclusion: Combined aspirin and clopidogrel non-responsiveness is
found in almost 12% of Pts. The only clinical predictor is weight>75kg.
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Purpose: Chronic total occlusion (CTO) remains one of the last frontiers
of percutaneous coronary intervention (PCI). Recently, a novel “soft”
guidewire (GW) developed for tracking invisible micro-channels (Fielder XT)
became available in France. The purpose of this study was to clarify the risk
factors contributing to PCI success for CTO lesions and evaluate the efficacy
and safety of this GW.
Methods: The study included 166 consecutive Pts with CTO’s (European
CTO Club definition) who underwent primary PCI at our institution between
June 2008 and Feb 2010 by 2 experienced operators. The cohort was divided
into 2 groups: group 1 (n=83), treated before availability of “Fielder XT” GW
in France and group 2 (n=83), treated since availability.
Results: Clinical and angiographic characteristics were similar in both
groups (age 63.9±11.3years, lesion length 23.0±18.1mm, bridging collateral
37.%, tortuosity score 0.16±0.37/1 and calcification score 0.94±1.08/3).
Fielder XT was used in 1 case (1.2%) in group 1 and 67 (80.7%) in group 2.
Micro catheters were used more frequently in group 2 (73.2% vs 56.6%;
p=0.013) and parallel wire technique was less required (16.2% vs 31.3%;
p=0.011). Angiographic success rate was significantly higher in group 2
(84.3% vs 67.5%; p=0.005) with a lower rate of dissection (12.2% vs 24.7%;
p=0.02) and a trend for a lower rate of perforation (4.9% vs 1.2%; p=ns). Pre-
dictors of failure in the total cohort were by multivariate logistic regression
analysis: proximal tortuosity (p=0.048, OR=3.15), absence of bifurcation
(p=0.024, OR=3.39), no visible stump (p<0.0001, OR=6.25), calcification
(p=0.029, OR=1.56) and patient in group 1 (p=0.015, OR=3.37).
Conclusion: Introduction of a dedicated “soft” wire in the CTO treatment
strategy improves the angiographic success rate of PCI with a more simple and
“soft” technique. Multivariate analysis confirmed classical independent predic-
tors of failure but also demonstrated that a new device may influence success
rate.
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Background: Premature discontinuation of antiplatelet therapy is a major
risk factor of stent thrombosis after drug-eluting stent placement leading to an
increased risk of death.
Objectives: We sought to determine by a simple questionnaire the preva-
lence of patients at risk for premature discontinuation of oral antiplatelet
therapy in elective percutaneous coronary intervention (PCI).
Methods: Patients scheduled for elective PCI underwent a routine inter-
view (RI) and a specific questionnaire (SQ) by two independent physicians the
day before the intervention. The SQ was designed to identify bleeding disor-
ders, suspected cancer, planned invasive procedures and self evaluation of
compliance. The final decision of drug eluting stent (DES) implantation was
made by a third independent physician who performed the planned PCI and
who had full access to the patient record. 
Results: At least one contraindication to DES implantation was found in
one third of the study population (82/302, 27%) after the RI. All these patients
were also identified by the SQ. At total of 31 additional patients were identi-
fied by the SQ as non eligible for DES implantation. Active bleeding (n=14)
and scheduled biopsies (n=4) were the two main contraindications to DES
implantation isolated by the SQ. Patients characteristics and angiographic find-
ings identified 59.9% patients (n=181/302) eligible for a DES implantation.
Finally the physician performing the PCI excluded 66.3% of the patients
(n=79/302) who could receive a DES and implanted a bare metal stent (BMS)
instead. This decision was based on the findings of the dedicated questionnaire
on top of the interview in 30 patients (38%) and in 49 patients (62%) for other
reasons.
Conclusions: In elective PCI, a simple questionnaire used before DES
implantation can improve identification of patients at high risk for premature
discontinuation of antiplatelet therapy.
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Background: Homocysteine has pro-thrombotic and pro-inflammatory
properties, it is a risk factor for cardiovascular disease. The prognostic value
of homocysteine in ST elevation myocardial infarction (STEMI) remains
uncertain. Aim: This study evaluates the predictive role of homocysteine level
on short and long term outcome in patients with STEMI. 
Methods and results: In this prospective cohort study, 186 consecutive
patients (mean age 58.4±12.6 years, 162 males, 65 diabetics) with STEMI
were enrolled. Plasma total homocysteine levels were measured within 24h
after admission. Inhospital complications: death, shock, left ventricular insuf-
Variable Double 
responders
Double 
non-responders
P
Male 191 (77.6%) 50 (86.2%) 0.15
Age(yrs) 67.3 +/-10.6 63.8+/-11.5 0.06
Weight (kg) 77.7+/-15.3 79.2+/-14.6 0.48
BMI 25.4+/-7.2 27.2+/-5.4 0.04
Smoking 89 (36.2%) 20 (35.5%) 0.81
Dyslipidaemia 152 (61.8%) 35 (61.4%) 0.96
Diabetes 52 (4.7%) 17 (6.1%) 0.22
Hypertension 159 (64.6%) 29 (50.1%) 0.06
Family history 18 (7.3%) 2 (3.5%) 0.20
Past PCI 88 (35.8%) 19 (33.3%) 0.73
Past CABG 9 (3.7%) 2 (3.5%) 0.96
Past MI 25 (10.1%) 11 (19.2%) 0.11
Weight <75kg 116 (46.8%) 18 (31.0%) 0.02
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ficiency or reinfarction were present in 46.8% of patients. Mean homocysteine
levels in patients with and without early complications were 22.99±19.01 and
17.93±7.08 µmol/l, p=0.018. The unadjusted hazard ratio of homocysteine
level > 12µmol/l was 2.4, IC95% [1.04-5.65]. Cox proportional hazards model
showed that plasma homocysteine was not an independent correlate of inhos-
pital complications (Hazard ratio=1.43, IC95% [0.37-5.53], p=0.6). The mean
follow-up period after discharge was 17.2 months [12 – 28.8 months], 43.2%
of patients presented a late complication: death, cardiac insufficiency or myo-
cardial infarction. Homocysteine wasn't significantly correlated with late com-
plications (mean levels in patients with and without late complications:
18.67±5.99 and 20.19±13.07µmol/l, p=0.43). 
Conclusion: Homocysteine levels measured in the acute phase of STEMI
are correlated only with early but not late outcome and it isn’t an independent
predictor of inhospital major cardiovascular major complications. 
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Purpose: The objective of this study was to describe utilisation of newly
prescribed statins in French primary care.
Methods: From February 2008 to July 2009, 272 French general practitio-
ners (GPs) included 2122 patients treated with a new statin, out of which 670
were treated with rosuvastatin. For each patient, demographic characteristics,
comorbidities, concomitant drug and biological characteristics were docu-
mented.
Results: The mean patient age was 62.6 and there were slightly more men
(54.6%) than women. The main cardiovascular risk factors (RF) were: hyper-
tension (50.3%), diabetes (22.7%), family history of premature cardiovascular
disease (22.5%) and smoking (17.4%). Nearly 3 GPs out of 4 declared they
provide life-style and nutritional advice before initiating the treatment ; only
44.5% gave diet booklets. GPs are the main first-time statins prescribers
(88.9%) in France. This percentage was higher for rosuvastatin than for the
others statins (93.2% vs. 86.8% ; p<0.001). Two thirds of the patients received
a statin for the first time following the diagnosis of dyslipidemia. One third
was switched to a new statin. The reasons for the switch were related to lack
of effectiveness of previous treatment and to intolerance to previous statins
(mainly muscle weakness or pain). Before initiating treatment, biochemical
analysis was performed in 91% of patients. And 3 to 6 months after statin ini-
tiation, lipid levels, transaminase levels and CPK were measured in 67%, 40%
and 28% of all patients, respectively. At that time, 57.1% of patients reached
the LDL-cholesterol according to risk categories distribution. The proportion
of patients reaching the target was higher in the rosuvastatin group than in the
others statins group (62.3% vs .54.6% ; p=0.016). Overall, the achievement of
LDL-cholesterol targets was lower in patients with higher CV risk (Table).
Conclusions: In real-life conditions, LDL treatment targets are reached in
less than 2/3 of patients treated with statin. Achievement of LDL targets is less
frequent in patients at high cardiovascular risk leaving much room for
improvement.
Table – Achievement of therapeutic LDL targets
High Risk
N=520
≥3 RF
N=55
2 RF
N=204
1 RF
N=213
0 RF
N=118
Total
N=1110
LDL-cholesterol target <1g/l <1.3g/l <1.6g/l <1.9g/l <2.2g/l
Proportion achieving
LDL goals 33.3% 47.3% 69.6% 85.0% 94.9% 57.1%
